Literature DB >> 1236626

Fibrinolytic activity in malignant disease.

J A Rennie, D Ogston.   

Abstract

Resting fibrinolytic activity and fibrinolytic capacity were compared in 31 patients with malignant disease and in 24 control subjects without malignant disease. Patients with malignant disease had a lower mean fibrinolytic activity: this was particularly marked in those with disseminated disease. In contrast, patients with malignant disease had a fibrinolytic capacity which did not differ from that of the control subjects.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1236626      PMCID: PMC475886          DOI: 10.1136/jcp.28.11.872

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  The histological localisation of fibrinolysin activator.

Authors:  A S TODD
Journal:  J Pathol Bacteriol       Date:  1959-07

2.  Studies on enhanced fibrinolytic activity in man.

Authors:  S SHERRY; R I LINDEMEYER; A P FLETCHER; N ALKJAERSIG
Journal:  J Clin Invest       Date:  1959-05       Impact factor: 14.808

3.  Urokinase an activator of plasminogen from human urine. I. Isolation and properties.

Authors:  J PLOUG; N O KJELDGAARD
Journal:  Biochim Biophys Acta       Date:  1957-05

4.  The significance of fibrinolysis occurring in patients with metastatic cancer of the prostate.

Authors:  H J TAGNON; W F WHITMORE; P SCHULMAN; S C KRAVITZ
Journal:  Cancer       Date:  1953-01       Impact factor: 6.860

5.  Fibrinolysis in metastatic cancer of the prostate.

Authors:  H J TAGNON; W F WHITMORE; N R SHULMAN
Journal:  Cancer       Date:  1952-01       Impact factor: 6.860

6.  Fibrinolytic activity of human veins.

Authors:  M Pandolfi; I M Nilsson; B Robertson; S Isacson
Journal:  Lancet       Date:  1967-07-15       Impact factor: 79.321

7.  Coagulation disorders in cancer. 3. Fibrinolysis and inhibitors.

Authors:  B C Soong; S P Miller
Journal:  Cancer       Date:  1970-04       Impact factor: 6.860

8.  "Fibrinolytic capacity" in healthy volunteers as estimated from effect of venous occlusion of arms.

Authors:  B R Robertson; M Pandolfi; I M Nilsson
Journal:  Acta Chir Scand       Date:  1972

9.  The fibrinolytic enzyme system in hepatic cirrhosis and malignant metastases.

Authors:  D Ogston; N B Bennett; C M Ogston
Journal:  J Clin Pathol       Date:  1971-12       Impact factor: 3.411

10.  FIBRINOLYSIS AND CARCINOMA OF THE PROSTATE.

Authors:  H T SWAN; D F KERRIDGE
Journal:  J Clin Pathol       Date:  1965-05       Impact factor: 3.411

  10 in total
  3 in total

1.  Identification of a plasminogen activator derived from nasopharyngeal carcinoma.

Authors:  T Kosugi; G W Huang; M Nakamura; S Koja; H T Nong
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

Review 2.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

3.  Role of P-selectin in thromboembolic events in patients with cancer.

Authors:  Lúcio Flávio Barbour Fernandes; José Humberto T G Fregnani; Célia Maria Cássaro Strunz; Adriana de Andrade Ramos Nogueira; Adhemar Longatto-Filho
Journal:  Mol Clin Oncol       Date:  2017-11-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.